Login
Israel-Hamas Conflict
Independence Day
Parade
Floods
Natural Disasters
World Cup
Real Madrid
Boxing
Social Media
Soccer
Music
Amazon
Immigration
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Eyewire+ image

News from Eyewire+

Information about Eyewire+

Where is Eyewire+ located?Eyewire+'s Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Eyewire+ News

UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative ...
Medical · Sheffield

UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative ...

34% Center coverage: 3 sources
Sheffield, July 01, 2025 (GLOBE NEWSWIRE) -See the Story
Startup That Makes Robots For Cataract Surgery Raises $125 Million In Second-Largest Fundraise For A Surgical Robotics Firm

Startup That Makes Robots For Cataract Surgery Raises $125 Million In Second-Largest Fundraise For A Surgical Robotics Firm

100% Center coverage: 2 sources
Millions of people get cataract surgery every year. What if a robot could do it better than humans?See the Story
Clinical Decision-Making in DED: Evaluating Tear Film Stability With Varenicline Nasal Spray Solution
Photography · United States

Clinical Decision-Making in DED: Evaluating Tear Film Stability With Varenicline Nasal Spray Solution

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear film quality and ocular surface health within days, offering a valuable treatment option for patients with aqueous-deficient dry eye despite no significant changes in tear breakup time.See the Story

FELIQS Announces $9 Million Series A Financing to Advance FLQ-101 Clinical Program for Retinopathy of Prematurity

Fukuoka, Japan and New York, New York--(Newsfile Corp. - July 1, 2025) - FELIQS Corporation ('FELIQS'), a biotechnology company developingUnited States · United StatesSee the Story

Formycon and Bio Usawa Partner Bio to Provide FYB201/ BioUcenta (Ranibizumab) Across Sub-Saharan Africa

Formycon announced a partnership between Bioeq AG—licensee and exclusive global commercialization rights holder for Formycon’s biosimilar FYB201—and African biotechnology company Bio Usawa Biotechnology. The agreement grants Bio Usawa exclusive rights to register and commercialize FYB201 under the brand name BioUcenta across Sub-Saharan Africa. Financial terms of the deal were not disclosed.  BioUcenta (biosimilar to Lucentis [ranibizumab]) is a…See the Story

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi Inc.

Eyenovia announced a rebrand to Hyperion DeFi Inc., signaling a pivot toward decentralized finance. The rebranding reflects Hyperion DeFi’s cryptocurrency treasury reserve strategy, centered around HYPE, the native token of the Hyperliquid blockchain and decentralized exchange. Effective July 3, 2025, the company’s common stock will trade under the new ticker symbol “HYPD” on the Nasdaq Capital Market. “Our new identity as Hyperion DeFi, Inc. re…Finance · United StatesRead Article

Glaukos Announces European Union MDR Certification for iStent infinite and iStent inject W

Glaukos received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite, along with several of its other MIGS technologies, including iStent inject W. Glaukos received FDA 510(k) clearance for the iStent infinite Trabecular Micro-Bypass System in 2022. The iStent infinite is indicated for use in a standalone procedure to reduce elevated IOP in patients with primary open-angle glaucoma uncontrolled by prior medical …European UnionRead Article

The European Commission (EC) Approves Eylea 8 mg for Extended Treatment Intervals of Up to 6 Months

The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8 mg with extended treatment intervals of up to 6 months for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Eylea 8 mg was previously approved for administration at extended treatment intervals of up to every 4 months, following 3 initial monthly doses. Eylea 8 mg is the first and only anti-vascular endot…AMDRead Article

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial

Nicox SA announced the completion of patient treatment and follow-up in the Denali phase 3 clinical trial for NCX 470, its lead candidate for the treatment of open-angle glaucoma and ocular hypertension. In total, 696 patients were enrolled across the United States and China. Topline results from the trial are expected between mid-August and mid-September 2025. “Reaching the milestone of the last patient last visit in the Denali phase 3 trial is…United States · United StatesRead Article

Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet AMD

Ashvattha Therapeutics announced interim results from its ongoing phase 2 study of subcutaneous (subQ) migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The data were presented at the MaculArt Meeting, June 29–July 1, 2025 in Paris. MGB represents a potential alternative to current standard of care, which requires patients to receive intravitreal injections every 4 to 12 weeks …AMD · ParisRead Article

Viatris’ Presbyopia Drug Clears Second Phase III Trial

There are only two therapies approved for presbyopia in the US.The post Viatris’ presbyopia drug clears second Phase III trial appeared first on Clinical Trials Arena.See the Story

Breaking News Topics Related to Eyewire+

AMD icon

AMD

Maryland icon

Maryland

Canada icon

Canada

Medical icon

Medical

United States icon

United States

News
For You
SearchBlindspotLocal